Aptamer Group develops Optimer® binders to enable innovation in the life science industry. Optimer binders are oligonucleotide-based affinity binders for use in research, diagnostics, therapeutics and bioprocessing. Combining high target affinity and selectivity, with an expanded target range and the highest batch consistency the fully in vitro Optimer discovery and development platform is supporting new and improved solutions.
Location: United Kingdom, England, Heslington
Employees: 11-50
Total raised: $4.63M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | Meneldor | meneldor.n... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 31.07.2023 | IPO | $4.63M | - |
Mentions in press and media 3
| Date | Title | Description |
| 31.07.2023 | Aptamer Group Scoops £3.6M in Recent Post-IPO Equity Fundraise | Key Takeaways: Aptamer Group, a biotechnology startup, has raised £3.6 million in a recent funding round. The funding round, which was through Post-IPO equity, marked the company’s third. The York-based company focuses on developing DNA and... |
| 22.12.2021 | Aptamer IPO: the next Biotech stock to watch? | Biotech stock Aptamer is launching its IPO on 22 December. Is this the next Biotech stock to watch? |
| 25.08.2021 | Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing | Aptamer Group and Bio-Works Technologies partner to enable improved solutions for gene therapy manufacturing Wed, Aug 25, 2021 10:00 CET York, UK and Uppsala, Sweden (August 25, 2021) Aptamer Group Ltd, the developer of custom affinity tool... |